10-Q - OTR Acquisition Corp. (0001821318) (Filer)

– Business combination transaction with OTR Acquisition Corp., a special purpose acquisition company, completed – – Combined company Comera Life Sciences Holdings, Inc. will be listed on the Nasdaq Capital Market under ticker symbol "CMRA" – Comera Life Sciences Holdings, Inc. ("Comera" or the "Company"), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced the completion of its business combination with OTR Acquisition Corp. (NASDAQ:OTRAU, OTRA and OTRAW))) (referred herein as "OTR"), a publicly traded special purpose acquisition company (SPAC). Comera Life Sciences Holdings, Inc., the resulting comb

Special meeting of OTR stockholders scheduled for May 10, 2022 Comera Life Sciences, Inc. ("Comera"), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, and OTR Acquisition Corp. (NASDAQ:OTRA) ("OTR"), a publicly traded special purpose acquisition company (SPAC), today announced that the Securities and Exchange Commission ("SEC") has declared the Registration Statement on Form S-4 filed in connection with the proposed business combination between the two companies, to be effective. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220418005109/en/ A special

Investor Call Rescheduled to Tuesday, Feb. 8 at 8:30 a.m. EST to Discuss Combination between Comera Life Sciences, Inc. and OTR Acquisition Corp. OTR Acquisition Corp. (NASDAQ:OTRAU, OTRA and OTRAW))), a publicly traded special purpose acquisition company (SPAC), today announced the confidential submission with the U.S. Securities and Exchange Commission ("SEC") of a draft registration statement on Form S-4 (the "Registration Statement") relating to its previously announced proposed business combination with Comera Life Sciences, Inc. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220203006027/en/ In addition, the investor call

Comera Life Sciences is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience This transaction is expected to enable further investment in a compassionate new era in medicine by applying a deep knowledge of formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms and thereby give patients greater flexibility in their care Combined company to have an implied initial equity value of approximately $258.4 million translating into an enterprise value of approximately $151.3 million, with the proposed business combination expected to provide approximately $107 million in g